RxDoctor Payments Data

Jarena Kelly, APRN

Family · South Charleston, WVNPI 1235246729

Payments from drug & device makers

$2,081in general payments, 2019–2025

Across 107 payments — averaging $19.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$687
  • AbbVie$210
  • AstraZeneca$174
  • Phathom Pharmaceuticals, Inc.$95
  • Sanofi-aventis U.S. LLC$93
  • Novartis$84
  • plus $738 from 19 others

What the payments were for

  • Food & beverage$2,081100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,081 in reported general payments places this provider in the 80th percentile of 1,507 family providers in West Virginia.

See all family providers in West Virginia

Medicare billing

Part B allowed, 2024
$6,646
Medicare patients
28
Services billed
119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide17$21,710
EliquisApixaban19$14,742
OzempicSemaglutide15$14,245
Tresiba Flextouch U-100Insulin Degludec15$7,499
Gabapentin47$596
Albuterol Sulfate HfaAlbuterol Sulfate13$374
Metformin Hcl ErMetformin Hcl16$308
Tramadol Hcl50$290
Trazodone Hcl23$287
Omeprazole35$262
Tizanidine Hcl15$260
Buspirone Hcl14$249
Levothyroxine Sodium22$215
Famotidine15$201
Atorvastatin Calcium28$200

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$75$21,71017 claims
Novo NordiskOzempic$687$14,24515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,507 family providers in West Virginia.

Other family in South Charleston

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →